Publications by Professor Deborah Tweddle - ePrints

Browsing publications by Professor Deborah Tweddle.

Newcastle Authors	Title	Year
Dr Anna Basu Professor Deborah Tweddle	A Case of High Risk Neuroblastoma Presenting after Completion of Treatment for Opsoclonus Myoclonus Ataxia Syndrome	2024
Professor Deborah Tweddle Dr Vickyanne Carruthers Hany Gabra	Management of Ganglioneuroma and Ganglioneuroblastoma Intermixed: A United Kingdom Children's Cancer and Leukaemia Group (UK CCLG) Nationwide Study Report	2024
Dr Leigh McDonald Angharad Goodman Professor Deborah Tweddle	Spontaneous regression of a greater than 5 cm infant neuroblastoma after a three-fold volume increase without life- or organ-threatening features	2024
Dr Lindi Chen Professor Deborah Tweddle	Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models	2023
Dr Shelby Barnett Professor Deborah Tweddle Professor Gareth Veal	Generation of evidence-based carboplatin dosing guidelines for neonates and infants	2023
Ruby Barford Fang Fong Hannah Hartley Dr Lisa Allinson Professor Deborah Tweddle et al.	Use of Optical Genome Mapping to Detect Structural Variants in Neuroblastoma	2023
Dr Shelby Barnett Dr Vickyanne Carruthers Professor Deborah Tweddle Professor Gareth Veal	Clinical pharmacology of cytotoxic drugs in neonates and infants: providing evidence-based dosing guidance	2022
Wen Hao Professor Deborah Tweddle Dr Ed Schwalbe Dr Gordon Strathdee	Genome wide DNA methylation analysis identifies novel molecular subgroups and predicts survival in neuroblastoma	2022
Dr Lisa Allinson Aaron Potts Dr Matthew Bashton Nermine Basta Dr Al Gabriel et al.	Loss of ALK hotspot mutations in relapsed neuroblastoma	2022
Professor Deborah Tweddle	Neuroblastoma: a master of disguise and a challenge to cure	2022
Dr Louise Hayes Nermine Basta Dr Colin Muirhead Paul Gibson Professor Deborah Tweddle et al.	Temporal clustering of neuroblastic tumours in children and young adults from Ontario, Canada	2022
Dr Shelby Barnett Professor Deborah Tweddle Professor Gareth Veal	Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients	2022
Dr Nicholas Bown Professor Deborah Tweddle	Frequency and Prognostic Impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) High Risk Neuroblastoma trial (HRNBL-1)	2021
Harriet Southgate Dr Lindi Chen Professor Nicola Curtin Professor Deborah Tweddle	Increased replication stress determines ATR inhibitor sensitivity in neuroblastoma cells	2021
Professor Gareth Veal Professor Deborah Tweddle Julie Errington	Pharmacokinetics and safety of a novel oral liquid formulation of 13-cis retinoic acid in children with neuroblastoma: A randomized crossover clinical trial	2021
Dr Nicholas Bown Professor John Lunec Professor Deborah Tweddle	Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group	2020
Harriet Southgate Dr Lindi Chen Professor Deborah Tweddle Professor Nicola Curtin	ATR inhibition potentiates parp inhibitor cytotoxicity in high risk neuroblastoma cell lines by multiple mechanisms	2020
Swathi Merugu Dr Lindi Chen Elizabeth Gavens Hany Gabra Dr Al Gabriel et al.	Detection of circulating and disseminated neuroblastoma cells using the Imagestream Imaging Flow Cytometer for use as predictive and pharmacodynamic biomarkers	2020
Hannah Smith Harriet Southgate Professor Deborah Tweddle Professor Nicola Curtin	DNA damage checkpoint kinases in cancer	2020
Harriet Southgate Dr Lindi Chen Professor Nicola Curtin Professor Deborah Tweddle	Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma	2020
Nermine Basta Dr Richard McNally Professor Deborah Tweddle	A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma	2019
Dr Lindi Chen Philip Berry Dr Jennifer Bonner Calum Kirk Dr Katrina Wood et al.	Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma	2019
Professor Gareth Veal Julie Errington Dr Leigh McDonald Professor Deborah Tweddle	The use of pharmacokinetically guided carboplatin chemotherapy in a pre-term infant with neuroblastoma-associated spinal cord compression	2019
Dr Lindi Chen Arman Esfandiari Professor John Lunec Professor Deborah Tweddle	Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours	2018
Dr Jane Carr-Wilkinson Dr Nilendran Prathalingam Dr Deepali Pal Dr Mohammad Moad Dr Peter James et al.	Differentiation of human embryonic stem cells to sympathetic neurons: A model for understanding neuroblastoma pathogenesis.	2018
Professor Deborah Tweddle	Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project	2017
Dr Lindi Chen Philip Berry Dr Jennifer Bonner Dr Katrina Wood Professor Gareth Veal et al.	In vivo evaluation of the intravenous MDM2-p53 antagonist RO6839921 alone and in combination with temozolomide in TP53 wild-type orthotopic models of neuroblastoma	2017
Dr Al Gabriel Dr Lindi Chen Dr Sirintra Nakjang Dr Daniel Williamson Professor Deborah Tweddle et al.	Combined Copy Number and Gene Expression Profiling in High Rick Neuroblastoma: A CCLG Pilot Biological Study	2016
Hayley Bowyer Professor Catherine Exley Melissa Girling Professor Deborah Tweddle	Delays to Diagnosis of Childhood Cancer: A Qualitative Study of Specialist Health Care Professionals' Views	2016
Nermine Basta Dr Gail Halliday Richard Feltbower Dr Nicholas Bown Professor Andrew Pearson et al.	Factors associated with recurrence and survival length following relapse in patients with neuroblastoma	2016
Dr Lindi Chen Angharad Humphreys Dr Lisa Turnbull Dr Nicholas Bown Professor Deborah Tweddle et al.	Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse	2016
Angharad Humphreys Dr Al Gabriel Dr Nicholas Bown Dr Lindi Chen Dr David Jamieson et al.	Imaging flow-cytometer based detection of ALK and MDM2 amplification in neuroblastoma cell lines	2016
Professor Deborah Tweddle	Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma	2016
Alison Page Dr Ghada Malik Dr Andrew Hall Professor Deborah Tweddle	The National Children's Cancer and Leukaemia Group Tissue Bank similar to Facilitating a Comprehensive Range of Paediatric Oncology Research	2016
Professor Gareth Veal Julie Errington Dr James Hayden Professor Deborah Tweddle	Carboplatin therapeutic monitoring in preterm and full-term neonates	2015
Professor Gareth Veal Julie Errington Dr James Hayden Professor Deborah Tweddle	Carboplatin therapeutic monitoring in preterm and full-term neonates	2015
Dr Nicholas Bown Professor John Lunec Professor Deborah Tweddle	Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification	2015
Dr Lindi Chen Professor Deborah Tweddle	Neuroblastoma and the p53 Pathway	2015
Dr Lindi Chen Professor Deborah Tweddle	Neuroblastoma and the p53 pathway	2015
Dr Lindi Chen Professor Herbie Newell Professor John Lunec Professor Deborah Tweddle	Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma	2015
Laura Evans Dr Lindi Chen Dr Elaine Willmore Professor Herbie Newell Professor Deborah Tweddle et al.	SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma	2015
Andrew Shouksmith Laura Evans Professor Deborah Tweddle Duncan Miller Dr Elaine Willmore et al.	Synthesis and Activity of Putative Small-Molecule Inhibitors of the F-Box Protein SKP2	2015
Dr Colin Muirhead Professor Deborah Tweddle Nermine Basta Dr Richard McNally	Temporal clustering of neuroblastic tumours in children and young adults from Northern England	2015
Professor Gareth Veal Julie Errington Professor Deborah Tweddle	Therapeutic drug monitoring approaches to the treatment of preterm and full-term neonates with cancer - A UK experience	2015
Professor Deborah Tweddle	Adherence to UK Children's Cancer and Leukaemia Group Guidelines for the Management of Low and Intermediate Risk Neuroblastoma, 2011-2013	2014
Nermine Basta Richard Feltbower Dr Peter James Professor Deborah Tweddle Dr Richard McNally et al.	Characteristics of UK patients with relapsed, intermediate risk unresectable, non-MYCN amplified neuroblastoma: a pilot study	2014
Dr Emma Bell Dr Frida Ponthan Claire Whitworth Professor Deborah Tweddle Professor John Lunec et al.	COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib	2014
Andrew Shouksmith Laura Evans Professor Roger Griffin Emeritus Professor Bernard Golding Professor Herbie Newell et al.	Design and synthesis of putative small-molecule inhibitors targeting the SCFSKP2 E3 ligase complex	2014
Professor Deborah Tweddle Professor Andrew Pearson	MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance	2014
Dr Lindi Chen Dr Yan Zhao Dr Gail Halliday Philip Berry Professor Herbie Newell et al.	Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma	2014
Dr Colin Muirhead Professor Deborah Tweddle Dr Richard McNally	Temporal Clustering of Neuroblastoma in Children and Young People from Northern England	2014
Nidal Boulos Dr Michael Tilby Professor Deborah Tweddle Professor John Lunec	Identification and characterisation of STMN4 and ROBO2 gene involvement in neuroblastoma cell differentiation	2013
Dr Lindi Chen Professor Deborah Tweddle	p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance	2012
Nermine Basta Dr Gail Halliday Richard Feltbower Dr Nicholas Bown Professor Andrew Pearson et al.	Factors associated with recurrence and length of survival following relapse in patients with neuroblastoma: a pilot study	2012
Professor Deborah Tweddle Professor John Lunec	MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63	2012
Dr Jonathan Fisher Professor Deborah Tweddle	Neonatal neuroblastoma	2012
Professor Deborah Tweddle	The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform	2012
Dr Nicholas Bown Professor John Lunec Professor Deborah Tweddle	A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma	2011
Dr Jane Carr-Wilkinson Bojidar Goranov Dr Chris Redfern Dr Laura Gamble Professor John Lunec et al.	Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression	2011
Dr Simon Bomken Dr Barry Davies Mike Cole Dr Katrina Wood Maritsa McDermott et al.	Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival	2011
Professor Deborah Tweddle Dr Katia Mazzocco	Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)	2011
Rachel Daniel Dr Agata Rozanska Dr Evan Mulligan Dr Yvette Drew Huw Thomas et al.	Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699	2010
Dr Jane Carr-Wilkinson Kieran O'Toole Angela Baker Julian Board Mike Cole et al.	High frequency of p53/MDM2/p14^ARFpathway abnormalities in relapsed neuroblastoma	2010
Dr Emma Bell Dr Lindi Chen Professor John Lunec Professor Deborah Tweddle	MYCN oncoprotein targets and their therapeutic potential	2010
Dr Lindi Chen Dr Laura Gamble Professor John Lunec Professor Deborah Tweddle	p53 is a direct transcriptional target of MYCN in neuroblastoma	2010
Dr Agata Rozanska Dr Evan Mulligan Huw Thomas Deborah Castelbuono Professor Deborah Tweddle et al.	[abstract] Central nervous system (CNS) penetration, poly-ADP ribose polymerase (PARP) inhibition and enhancement of temozolomide activity against childhood medulloblastoma by AG-014699	2009
Dr Agata Rozanska Huw Thomas Dr Evan Mulligan Dr Yvette Drew Deborah Castelbuono et al.	Inhibition of Poly (ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma	2009
Dr Katrina Wood Dr Michael Jackson Dr Maria Lastowska Dr Darroch Hall Dr Helen Imrie et al.	Histological profile of tumours from MYCN transgenic mice	2008
Dr Emma Bell Professor John Lunec Professor Deborah Tweddle	Cell cycle regulation targets of MYCN identified by gene expression microarrays	2007
Dr Jane Carr-Wilkinson Dr Nicholas Bown Marian Case Dr Andrew Hall Professor John Lunec et al.	High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays	2007
Dr Maria Lastowska Dr Mauro Santibanez Koref Ilka Wappler Dr Heiko Peters Dr Andrew Hall et al.	Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data	2007
Dr Lindi Chen Professor Archibald Malcolm Dr Katrina Wood Mike Cole Professor Andrew Pearson et al.	p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma	2007
Professor Steven Clifford Rachel Daniel Dr Agata Rozanska Huw Thomas Professor Alan Boddy et al.	Preclinical evaluation of the POLY-ADP ribose polymerase 1 (PARP-1) inhibitor AG014699 in combination with topotecan and temozolomide for the treatment of medulloblastoma and neuroblastoma	2007
Dr Simon Bomken Dr Barry Davies Dr Katrina Wood Professor Deborah Tweddle	Tumour necrosis following chemotherapy in neuroblastoma correlates with MYC-N status but not survival	2007
Dr Jane Carr-Wilkinson Dr Emma Bell Professor Andrew Pearson Professor John Lunec Professor Deborah Tweddle et al.	Increased frequency of aberrations in the p53/MDM2/p14ARF pathway in neuroblastoma cell lines established at relapse	2006
Dr Simon Bomken Dr Katrina Wood Dr Michael Reid Professor Deborah Tweddle	Limitations in the ability of NB84 to detect metastatic neuroblastoma cells in bone marrow	2006
Dr Emma Bell Dr Jane Carr-Wilkinson Dr Xiaohong Lu Professor Penny Lovat Professor John Lunec et al.	The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage	2006
Dr Jayne Lamont Professor Deborah Tweddle Professor Andrew Pearson Professor Steven Clifford Professor David Ellison et al.	A 7-year-old boy with midline cerebellar mass	2005
Dr Tibor Nyari Professor Andrew Pearson Professor Deborah Tweddle Julian Board	Large cell neuroblastoma: A distinct phenotype of neuroblastoma with aggressive clinical behavior	2004
Professor Deborah Tweddle	MYCN amplification remains prognostically strong 20 years after its clinical debut	2004
Professor Deborah Tweddle Julian Board Professor Andrew Pearson Professor John Lunec	Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[131I]iodobenzylguanidine by neuroblastoma tumors	2003
Dr Jane Carr-Wilkinson Julian Board Dr Katrina Wood Professor Andrew Pearson Professor John Lunec et al.	Selection for p53 mutant cells by chemotherapy in high-risk neuroblastoma	2003
Professor Deborah Tweddle Professor Andrew Pearson Professor John Lunec	The p53 pathway and its inactivation in neuroblastoma	2003
Professor Deborah Tweddle Professor Archibald Malcolm Dr Nicholas Bown Professor Andrew Pearson Professor John Lunec et al.	Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line	2001
Professor Deborah Tweddle Mike Cole Professor Andrew Pearson	OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age	2001
Professor Deborah Tweddle Professor Archibald Malcolm Mike Cole Professor Andrew Pearson Professor John Lunec et al.	p53 cellular localization and function in neuroblastoma: evidence for defective G1 arrest despite WAF1 induction in MYCN-amplified cells	2001
Professor Deborah Tweddle Dr Kevin Windebank	Cyclosporin neurotoxicity after chemotherapy: Reply	1999
Professor Deborah Tweddle Dr Jennifer Kernahan	Cerebral candidiasis in a child 1 year after leukaemia	1998
Professor Deborah Tweddle Professor Andrew Pearson Professor Archibald Malcolm Professor John Lunec	Does TP53 function in neuroblastoma?	1998
Professor Deborah Tweddle Dr Stephen Pedler	Non-tuberculous mycobacterial infection in children with cancer	1998
Professor Deborah Tweddle Professor Archibald Malcolm Dr Michael Reid Mike Cole Professor John Lunec et al.	TP53 and related protein expression in primary and metastatic neuroblastoma	1998
Professor Deborah Tweddle Dr Kevin Windebank Andrew Barrett	Central venous catheter use in UKCCSG oncology centres	1997
Professor Deborah Tweddle Dr Michael Reid	Aplastic anaemia in the northern region of England	1996
Professor Deborah Tweddle	Electron microscopy and serological features of a patient with Q fever prosthetic valve endocarditis.	1996
Professor Deborah Tweddle	Dementia presenting with sore eyes	1992